tiprankstipranks
Advertisement
Advertisement

TSE:PHRM Stock Latest News

PharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
Company AnnouncementsPharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
4d ago
PharmaTher Targets U.S. Peptide Market With Expansion of PharmaPatch Microneedle Platform
PremiumCompany Announcements
PharmaTher Targets U.S. Peptide Market With Expansion of PharmaPatch Microneedle Platform
27d ago
PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
PremiumCompany Announcements
PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
2M ago
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
PremiumCompany Announcements
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
2M ago
PharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win
PremiumCompany Announcements
PharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win
3M ago
PharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program
PremiumCompany AnnouncementsPharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program
4M ago
PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders
Premium
Company Announcements
PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders
4M ago
PharmaTher Poised for Growth as FDA Prioritizes Ketamine
Premium
Company Announcements
PharmaTher Poised for Growth as FDA Prioritizes Ketamine
5M ago
PharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment
PremiumCompany Announcements
PharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment
5M ago
PharmaTher Launches AI Platform to Expand Ketamine Portfolio
PremiumCompany Announcements
PharmaTher Launches AI Platform to Expand Ketamine Portfolio
6M ago
PharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia
PremiumCompany Announcements
PharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia
6M ago
Psychedelic: Enveric announces EB-003 manufacturing milestones
PremiumThe Fly
Psychedelic: Enveric announces EB-003 manufacturing milestones
6M ago
ENVB
NRXP
PharmaTher Advances Ketamine Strategy with Strategic Asset Sale
PremiumCompany AnnouncementsPharmaTher Advances Ketamine Strategy with Strategic Asset Sale
6M ago
PharmaTher provides update on ketamine development, commercial strategy
Premium
The Fly
PharmaTher provides update on ketamine development, commercial strategy
6M ago
PharmaTher Sells Ketamine ANDA with Potential $25 Million Upside
Premium
Company Announcements
PharmaTher Sells Ketamine ANDA with Potential $25 Million Upside
6M ago
PharmaTher announces sales of ketamine ANDA
PremiumThe Fly
PharmaTher announces sales of ketamine ANDA
6M ago
PharmaTher Advances Ketamine Patch for Non-Opioid Pain Relief
PremiumCompany Announcements
PharmaTher Advances Ketamine Patch for Non-Opioid Pain Relief
7M ago
PharmaTher Advances U.S. Market Strategy Following FDA Approval of KETARx™
PremiumCompany Announcements
PharmaTher Advances U.S. Market Strategy Following FDA Approval of KETARx™
7M ago
PharmaTher provides update following FDA approval of ketamine
PremiumThe Fly
PharmaTher provides update following FDA approval of ketamine
7M ago
Psychedelic: atai Life Sciences, Cybin report earnings results
PremiumThe FlyPsychedelic: atai Life Sciences, Cybin report earnings results
8M ago
ATAI
CYBN
PharmaTher Receives FDA Approval for KETARx™, Paving Way for New Opportunities
Premium
Company Announcements
PharmaTher Receives FDA Approval for KETARx™, Paving Way for New Opportunities
8M ago
PharmaTher issues letter to shareholders
Premium
The Fly
PharmaTher issues letter to shareholders
8M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >